Velagliflozin (Senvelgo) for Feline Diabetes Mellitus: SGLT2 Inhibition, Efficacy and Safety

Bottom line

• Velagliflozin (Senvelgo) is an oral, once-daily SGLT2 inhibitor for the insulin-naïve diabetic cat. In the pivotal SENSATION field trial (n=252 client-owned cats, 85% insulin-naïve), median blood glucose fell from 436 mg/dL at screening to 153 mg/dL by day 30 and 125 mg/dL by day 180; at day 180, ~81% of remaining cats had blood glucose and/or fructosamine within reference range.[1]
• The class hazard is euglycemic diabetic ketoacidosis (eDKA), not hypoglycemia. Ketoacidosis struck ~7% of SENSATION cats — the same order as DKA in insulin-treated cats — and ~78% of those events were euglycemic (blood glucose looked reassuring while the cat was acidotic). Nearly all events clustered in the first 14 days, and previously insulin-treated cats were at markedly higher risk (18.4% vs 5.1%).[1]
• The bexagliflozin data agree, confirming a class effect. The Bexacat pivotal trial (Hadd et al., n=84) showed ~84% treatment success with eDKA in ~5%, so the efficacy is reproducible across two independent molecules and the eDKA signal is not a one-drug fluke.[5]
• As of July 2026, both the 2026 AAHA feline guidelines and the 2025 iCatCare consensus endorse SGLT2 inhibitors as a first-line option for newly diagnosed, metabolically stable, insulin-naïve cats — with blood β-hydroxybutyrate (BHB) monitoring (days 2–3, 7, 14, 30) described as an essential part of safe use.[2][7]
• This is a clinician-facing evidence summary. It is not a dosing protocol; confirm regimen, monitoring thresholds, and contraindications against current product labeling, the full 2026 AAHA guidelines, and a veterinary formulary.

Drug facts

Attribute	Velagliflozin (Senvelgo)	Bexagliflozin (Bexacat)
Class	SGLT2 inhibitor[1]	SGLT2 inhibitor[5]
Mechanism	Blocks glucose reabsorption in the renal proximal convoluted tubule → urinary glucose excretion → insulin-independent glycemic lowering, reversing glucose toxicity and allowing beta-cell recovery[2]	Same mechanism[2][5]
Formulation / route	Oral solution (15 mg/mL), once daily, into the mouth or with a small amount of food[1]	Flavored 15 mg oral tablet, once daily[5]
FDA approval	August 2023 (Boehringer Ingelheim)[3]	January 2023 (Elanco) — first-ever oral feline diabetes drug[5]
Indication	Cats with DM not previously treated with insulin[3]	Cats newly diagnosed with DM not previously treated with insulin[5]
Core contraindications	Ketonuria on screening; systemic compromise (vomiting, hyporexia, cachexia, lethargy); significant CKD (IRIS Stage 3+); hepatopathy; hypercalcemia[2]	Same class contraindications; per label, do not start if blood BHB >3.6 mmol/L, or >2.4 mmol/L with a history of acidosis/renal compromise[5]

The 2026 AAHA Diabetes Management Guidelines for Cats identify SGLT2 inhibitors and insulin as the two licensed treatment modalities for feline DM, with SGLT2 inhibitors an appropriate first-line option for a substantial proportion of newly diagnosed, metabolically stable patients.[2] Traditional oral hypoglycemics (glipizide, metformin) are explicitly not recommended in cats — they are not consistently safe or effective.[2]

How well does velagliflozin control blood glucose? (efficacy)

The anchoring evidence is the SENSATION study (Behrend et al., JAVMA 2024) — a prospective, baseline-controlled, open-label field trial of 252 client-owned cats (214 insulin-naïve, 38 previously insulin-treated) dosed with once-daily oral velagliflozin over 180 days, with examinations and blood collection on days 0, 3, 7, 30, 60, 120, and 180. Screening blood glucose was 436 mg/dL (IQR 272–676).[1]

Median blood glucose after starting velagliflozin:[1]

• Day 30: 153 mg/dL (range 62–480)
• Day 60: 134 mg/dL (range 64–414)
• Day 120: 128 mg/dL (range 55–461)
• Day 180: 125 mg/dL (range 77–384)

At day 180, 81% of the 158 remaining cats had blood glucose and/or fructosamine within the reference range, and roughly 88% of owners reported resolution of polyuria and polydipsia.[1] Serum fructosamine is routinely within the reference range after ~8 weeks of therapy, and clinical signs improve in the majority of cats despite persistent (drug-induced) glucosuria.[2]

Distinctive benefit — peripheral neuropathy. Diabetic peripheral neuropathy (the plantigrade stance that limits a cat's ability to run and jump) improved in >75% of affected cats, consistent with reversal of glucose toxicity by sustained glycemic lowering.[1]

Velagliflozin vs insulin, and vs bexagliflozin (comparators)

Head-to-head vs insulin. A comparative randomised trial (Niessen et al., JVIM 2024) evaluated once-daily oral velagliflozin against twice-daily insulin injections in diabetic cats. Velagliflozin was non-inferior for glycemic control, with good quality-of-life and glycemia and no clinical hypoglycemia, while removing the twice-daily injection burden that drives real-world non-adherence.[4]

Cross-molecule consistency — bexagliflozin. The bexagliflozin pivotal trial (Hadd et al., JVIM 2023, n=84 newly diagnosed cats) showed the drug decreased hyperglycemia and clinical signs of DM, with ~84% treatment success at day 56 and eDKA in ~5%.[5] The 2026 AAHA guidelines treat bexagliflozin and velagliflozin as clinically equivalent for patient selection and monitoring, and the same monitoring schedule (guideline Table 6.1) applies to both agents.[2][5] The consistency across two independent molecules is what tells you the efficacy is real and the eDKA signal is a class effect.

Where insulin still wins. Insulin remains the appropriate therapy for any cat that is not metabolically stable, for previously insulin-treated cats (the highest-risk eDKA group), and for truly insulin-deficient cats that lack the residual beta-cell function SGLT2 inhibitors presume.[2][5]

Safety and adverse events (what to warn owners about)

Euglycemic DKA — the defining hazard

The most serious complication is DKA, most commonly euglycemic DKA (eDKA), in which acid-base and electrolyte derangements occur despite blood glucose <250 mg/dL.[1] Reported eDKA incidence with SGLT2 inhibitors is 5–7%, the same order as DKA in insulin-treated cats.[1][2] In SENSATION, ketonuria developed in 35 cats (13.9%) and ketoacidosis in 18 (7.1%); 14 of those 18 (77.8%) were euglycemic at diagnosis, and previously insulin-treated cats decompensated far more often (18.4% vs 5.1% in naïve cats).[1] Events cluster in the first 14 days. Affected cats are typically hyporexic and lethargic with blood BHB usually >2.4 mmol/L.[1][2]

A normal glucose does not exclude DKA in these patients. This is why glucose-based triage fails and blood BHB is mandatory. When eDKA is confirmed, treat it as any DKA but with the twist that the cat is already euglycemic — the reference approach is IV dextrose alongside a regular-insulin CRI; the Preteseille 2025 case report documents a textbook recovery on exactly this protocol, with discharge on glargine at day 9.[8]

Gastrointestinal effects

Roughly 38–50% of cats have changes in stool consistency within the first 2 weeks, attributed to mild cross-inhibition of intestinal SGLT1 causing osmotic diarrhea. It is typically modest and self-limiting; antibiotics are not indicated. Vomiting is commonly reported but sporadic — if the cat is eating well and stable, velagliflozin can be safely redosed after vomiting within 30 minutes of a dose.[1][2]

Other serious adverse events (bexagliflozin trial)

In the Hadd et al. bexagliflozin trial, serious adverse events occurred in ~10% of cats: DKA, pancreatitis, hepatic lipidosis, weight loss, urinary tract infections, dehydration, anemia, and hypercalcemia.[5] Modest increases in serum total calcium have been reported in a small number of cats on SGLT2 inhibitors; the 2026 AAHA guidelines recommend monitoring ionized calcium in cats with a history of hypercalcemia.[2] Notably, no clinical hypoglycemia occurred in SENSATION — the insulin-independent mechanism means these drugs do not drive hypoglycemia on their own.[1]

BHB monitoring — the intervention that makes the class safe

The 2026 AAHA guidelines state that BHB measurement is preferred over other methods for assessing ketosis and is an essential part of SGLT2 inhibitor monitoring; inexpensive handheld meters give quick, reliable blood BHB quantification. The currently validated ketone meter for cats is the Precision Xtra (Abbott).[2] Blood BHB — not urine dipsticks — is required, because dipsticks detect acetoacetate, lag the true metabolic state, and miss BHB (the dominant ketone early in decompensation).[2]

Recommended monitoring schedule (2026 AAHA, Table 6.1):[2]

Timepoint	Action / expectation
Baseline	Physical exam, BHB, renal panel, pancreatic lipase, CBC/chem/UA before the first dose
Days 2–3	BHB >2.4 mmol/L (≈25 mg/dL) → switch to insulin; BHB 1.0–2.4 mmol/L → recheck in 2–3 days
Day 7	Review history, BHB, spot-check BG
Day 14	Review history, BHB, BG; expect BG <250 mg/dL
Day 30	Review history, weight, BHB, BG, fructosamine; expect fructosamine normalization or significant improvement
Every 3 months	As for day 30

Guideline exceptions apply for a declining BHB in a clinically stable cat that started above 2.4 mmol/L. Owners must be told to call immediately for any lethargy, vomiting, or anorexia, regardless of how the cat "looks" — a cat that becomes anorexic on an SGLT2 inhibitor is a potential emergency until BHB proves otherwise.[1][2] A notable 2026 AAHA shift: routine in-hospital blood glucose curves are no longer recommended in cats, because stress hyperglycemia distorts readings; monitoring now emphasizes clinical signs, continuous glucose monitoring, and at-home data.[14]

Special populations

Previously insulin-treated cats (off-label, high-risk)

Transitioning an insulin-treated cat to an SGLT2 inhibitor is off-label and the highest-risk eDKA scenario (18.4% vs 5.1% ketoacidosis in SENSATION).[1] Do not routinely combine an SGLT2 inhibitor with insulin, and never simply stop insulin and start the tablet. If a transition is genuinely warranted, do it deliberately with intensive blood BHB monitoring.[1][6]

Non-ideal / comorbid candidates — evidence is emerging and cautionary

Real-world use is already outrunning the label. The Vanneste 2026 case series describes velagliflozin in seven "non-ideal" cats with CKD, acromegaly, and IBD: two achieved remission, but one developed eDKA within 48 hours and another became severely hypoglycemic on combined insulin therapy — underscoring that off-label use amplifies risk.[9] The 2025 iCatCare consensus and 2026 AAHA both keep the licensed indication narrow (metabolically stable, insulin-naïve) precisely because that is where the safety data are strongest.[2][7]

Glucocorticoid-associated diabetes — a strong SGLT2 candidate profile

Cats with a readily reversible cause of insulin resistance — such as recent depot/oral steroid administration — are particularly suitable SGLT2 candidates: they are more likely to enter remission and are therefore especially vulnerable to hypoglycemia if instead treated with insulin.[2] Glucocorticoids (notably prednisolone ≥2 mg/kg/day for >3–4 weeks) are a leading cause of secondary feline DM.[7] Cats are uniquely susceptible: naturally low first-phase insulin secretion, amyloid-prone/fragile beta cells, and — critically — obese cats reach ~2-fold higher plasma prednisolone concentrations than lean cats at the same dose (Lowe et al. 2013), amplifying the diabetogenic burden.[12] Glucocorticoid-induced DM is potentially reversible: Cha et al. (2024) documented remission within 60 days after tapering prednisolone to anti-inflammatory doses (0.5–1 mg/kg/day) and discontinuing ciclosporin.[11] Where the underlying disease permits, taper the steroid to the lowest effective dose, exclude hypersomatotropism (screen IGF-1 if insulin need >1.5 U/kg/injection), and consider a steroid-sparing agent.[7][11]

Diabetic remission — a feline-specific goal

As of July 2026, the 2026 AAHA guidelines define remission as euglycemia maintained >4 weeks without exogenous insulin or oral hypoglycemics; ~25% of cats achieve remission within 2–3 months of diagnosis, a majority within 6 months, and the task force supports an average US remission rate of ~30%.[10] Remission is almost exclusively feline — it depends on reversal of insulin resistance and glucose toxicity with beta-cell recovery — and cats with reversible IR (obesity managed with weight loss; recent glucocorticoid/progestogen withdrawal) are the most likely to remit.[10] Canned high-protein/low-carbohydrate diets may support remission (mitigating sarcopenia, boosting GLP-1).[10]

Two practical caveats: (1) Drug-induced glucosuria makes urine-glucose an unreliable remission signal in SGLT2-treated cats — the drug must be withheld to identify remission; check after ≥90 days of therapy using a CGM or 1–2 daily glucometer checks for at least a week, with BG persistently >250 mg/dL plus clinical signs indicating continued treatment is needed.[10] (2) Unrecognised remission in an insulin-treated cat is a life-threatening hypoglycemia hazard — remission is signalled by falling insulin requirements, glucosuria-negative for >48 h, or fructosamine at/below reference range, so owner education and regular glucose monitoring are essential.[10]

Contraindications, precautions & PK

Do not start an SGLT2 inhibitor in a cat with any of the following:[2][6]

• Ketonuria on screening, or baseline ketosis (serum BHB >2.4 mmol/L; bexagliflozin label: do not start if BHB >3.6 mmol/L, or >2.4 mmol/L with a history of acidosis/renal compromise)
• Systemic compromise: vomiting, hyporexia, cachexia, lethargy, dehydration
• Significant CKD — IRIS Stage 3+ (Cook & Behrend: azotemia thresholds of creatinine >177 µmol/L for velagliflozin, >250 µmol/L for bexagliflozin)
• Hepatopathy / marked hyperbilirubinemia
• Hypercalcemia
• Clinical pancreatitis or a markedly elevated Spec fPL
• Previously insulin-treated / insulin-dependent status (off-label; highest eDKA risk)

Pre-treatment workup: thorough physical exam plus CBC, chemistry panel, and urinalysis; screen cats >7 years for hyperthyroidism before starting.[2] Detecting ketonuria during treatment should prompt discontinuation and transition to insulin.[2][5]

Pharmacology. Both agents are highly selective SGLT2 inhibitors acting at the renal proximal convoluted tubule; efficacy presumes residual beta-cell function, so a truly insulin-deficient cat will not respond and may decompensate.[2][6] The mild GI signal reflects incidental SGLT1 cross-inhibition in the small intestine.[2] Cost is non-trivial — roughly $60–$110 per month — plus the added cost of owner-performed ketone monitoring.[6]

Practical decision support

Step 1 — Is this cat a candidate? The ideal patient is a newly diagnosed, well-appetited, well-hydrated, insulin-naïve cat with no ketosis and no significant comorbidity.[2][6] A cat with reversible IR (obesity, recent steroids) is an especially good fit and a poor insulin candidate (hypoglycemia risk on remission).[2]

Step 2 — Baseline before the first dose. BHB, renal panel, pancreatic lipase, CBC/chem/UA; hyperthyroid screen if >7 years.[2]

Step 3 — Front-load monitoring through day 14. Blood BHB (Precision Xtra), not urine dipsticks, at days 2–3, 7, 14, 30, then q3 months. Owner instruction: call immediately for any lethargy, vomiting, or anorexia.[1][2]

Step 4 — Act on the numbers. BHB >2.4 mmol/L → stop the drug, start insulin (allowing for the declining-BHB exception in a clinically stable cat who started high); BHB 1.0–2.4 mmol/L → recheck in 2–3 days.[2] Assess overall response at ~1 month — if the cat remains hyperglycemic with clinical signs, discontinue and provide insulin.[2]

Step 5 — If eDKA develops, treat as DKA plus IV dextrose with a regular-insulin CRI, because the cat is already euglycemic.[8]

Step 6 — Screen for remission after ≥90 days by withholding the drug and monitoring BG (CGM or 1–2 daily checks for ≥1 week).[10]

If the patient is a dog, not a cat: SGLT2 inhibitors are not the answer — canine DM is a beta-cell–deficient disease and remission is rare. Twice-daily intermediate-acting insulin remains standard, and the highest-quality comparative evidence (Fracassi et al. 2018, the only RCT of lente vs NPH in 30 newly diagnosed diabetic dogs) found the two similarly effective: good glycemic control at 12 weeks in 60% (lente) vs 73% (NPH), a non-significant difference. Median final dose per injection was 0.61 U/kg (lente) vs 0.49 U/kg (NPH) — titrated maintenance, not starting doses.[13] The choice between lente and NPH is therefore driven by availability, cost, compliance, and clinician experience rather than demonstrated superiority.[13]

Frequently Asked Questions

How effective is velagliflozin at lowering blood glucose in diabetic cats? In the SENSATION study (252 cats), median blood glucose fell from a screening value of 436 mg/dL to 153 mg/dL by day 30, 134 by day 60, 128 by day 120, and 125 mg/dL by day 180 on once-daily oral velagliflozin; at day 180 about 81% of remaining cats had blood glucose and/or fructosamine within reference range.[1]

What is the mechanism of action of velagliflozin? It is a highly selective SGLT2 inhibitor that blocks glucose reabsorption in the renal proximal convoluted tubule, promoting urinary glucose excretion and lowering blood glucose independently of endogenous insulin — mitigating clinical signs while reversing glucose toxicity and allowing beta-cell recovery.[2]

What are the main safety concerns with SGLT2 inhibitors in cats? The defining hazard is euglycemic DKA (~5–7% of treated cats, mostly in the first 2 weeks), where the cat is acidotic despite a normal-looking glucose. GI stool-consistency changes affect 38–50% of cats but are usually mild and self-limiting, and no clinical hypoglycemia occurred in the pivotal trial. Blood BHB monitoring at days 2–3, 7, 14, and 30 is essential.[1][2]

Can I switch a cat that is already on insulin to Senvelgo or Bexacat? Off-label and high-risk. Previously insulin-treated cats had an 18.4% ketoacidosis rate in SENSATION versus 5.1% in insulin-naïve cats. If you transition at all, do it deliberately with intensive blood BHB monitoring — never by simply stopping insulin and starting the tablet.[1]

How is euglycemic DKA different from classic DKA, and how do I treat it? The acidosis and ketonemia are identical, but blood glucose is normal or only mildly elevated, so glucose-based triage misses it — you must measure blood BHB. Treatment adds IV dextrose to the standard regular-insulin CRI because the cat is not hyperglycemic.[1][8]

Why blood β-hydroxybutyrate instead of urine ketones? Urine dipsticks detect acetoacetate and lag the true metabolic state, whereas BHB is the dominant ketone early in decompensation. Handheld blood BHB meters (Precision Xtra) catch trouble sooner and are the standard of care for cats on SGLT2 inhibitors.[2]

How does bexagliflozin compare with velagliflozin? Both are once-daily oral SGLT2 inhibitors with the same mechanism, indication, and eDKA risk profile; the 2026 AAHA guidelines treat them as clinically equivalent for patient selection and monitoring. Bexacat (tablet, FDA-approved January 2023) was the first oral feline diabetes drug; Senvelgo (oral solution, August 2023) followed. Bexagliflozin's pivotal trial showed ~84% success with serious adverse events in ~10% of cats.[2][5]

What is the diabetic remission rate in cats, and how do I detect it on an SGLT2 inhibitor? Per the 2026 AAHA guidelines, ~25% of cats remit within 2–3 months and the task force supports an average US rate of ~30%. Because SGLT2 inhibitors cause drug-induced glucosuria, urine glucose is unreliable — withhold the drug and screen after ≥90 days with a CGM or 1–2 daily glucometer checks for at least a week.[10]

Changelog

• 2026-07-06: Consolidated the velagliflozin/Senvelgo hub with six dated dispatch spokes (SGLT2-inhibitor class brief, glucocorticoid-induced feline DM, 2026 AAHA SGLT2 patient selection, bexagliflozin/Bexacat Hadd 2023, lente-vs-NPH canine insulin Fracassi 2018, and the 2026 AAHA diabetic-remission framework) into one evergreen reference. Deduplicated the shared SENSATION/AAHA evidence; folded in each spoke's distinct data (Niessen head-to-head, Hadd bexagliflozin, Preteseille eDKA case, Vanneste non-ideal candidates, iCatCare 2025 consensus, Cha/Lowe glucocorticoid PK and remission, AAHA remission framework, Fracassi canine insulin RCT). Citation correction: the Niessen JVIM 2024 head-to-head trial DOI was corrected from 10.1111/jvim.17106 (which resolves to an unrelated paper) to the verified 10.1111/jvim.17124.
• 2026-06-26: First published.